Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMPH NASDAQ:INDV NASDAQ:MOR NASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$18.41$20.10$16.65▼$31.26$811.70M0.97737,983 shs485,196 shsINDVIndivior$37.53$33.39$11.08▼$41.00$4.58B0.92.50 million shs1.06 million shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/AVKTXViking Therapeutics$30.89$32.95$22.96▼$43.15$3.59B0.722.30 million shs1.22 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals0.00%+9.13%-14.01%-33.18%-24.77%INDVIndivior0.00%+2.09%+12.85%+13.97%+233.30%MORMorphoSys0.00%0.00%0.00%0.00%0.00%VKTXViking Therapeutics0.00%+2.05%-5.68%-10.36%+14.49%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$18.41$20.10$16.65▼$31.26$811.70M0.97737,983 shs485,196 shsINDVIndivior$37.53$33.39$11.08▼$41.00$4.58B0.92.50 million shs1.06 million shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/AVKTXViking Therapeutics$30.89$32.95$22.96▼$43.15$3.59B0.722.30 million shs1.22 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals0.00%+9.13%-14.01%-33.18%-24.77%INDVIndivior0.00%+2.09%+12.85%+13.97%+233.30%MORMorphoSys0.00%0.00%0.00%0.00%0.00%VKTXViking Therapeutics0.00%+2.05%-5.68%-10.36%+14.49%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPHAmphastar Pharmaceuticals 1.88Reduce$24.5033.08% UpsideINDVIndivior 3.00Buy$39.334.81% UpsideMORMorphoSys 0.00N/AN/AN/AVKTXViking Therapeutics 2.85Moderate Buy$95.50209.16% UpsideCurrent Analyst Ratings BreakdownLatest VKTX, MOR, AMPH, and INDV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2026AMPHAmphastar Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$30.00 ➝ $19.005/11/2026AMPHAmphastar Pharmaceuticals Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$25.00 ➝ $21.005/8/2026AMPHAmphastar Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold5/6/2026INDVIndivior Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/1/2026VKTXViking Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$125.004/30/2026VKTXViking Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$95.004/30/2026VKTXViking Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$105.00 ➝ $100.004/27/2026VKTXViking Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/21/2026AMPHAmphastar Pharmaceuticals Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold$30.00 ➝ $22.004/20/2026VKTXViking Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/10/2026AMPHAmphastar Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPHAmphastar Pharmaceuticals$719.89M1.13$4.25 per share4.33$17.54 per share1.05INDVIndivior$1.29B3.55$2.72 per share13.80($1.18) per share-31.81MORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17VKTXViking TherapeuticsN/AN/AN/AN/A$4.32 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPHAmphastar Pharmaceuticals$98.09M$1.6611.095.632.9811.00%15.12%7.14%8/6/2026 (Estimated)INDVIndivior$210M$1.9519.2510.20N/A19.44%-219.26%29.40%7/30/2026 (Estimated)MORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/AVKTXViking Therapeutics-$359.64M-$4.14N/AN/AN/AN/A-71.31%-65.35%7/29/2026 (Estimated)Latest VKTX, MOR, AMPH, and INDV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026AMPHAmphastar Pharmaceuticals$0.70$0.42-$0.28$0.14$173.46 million$171.17 million4/30/2026Q1 2026INDVIndivior$0.64$0.96+$0.32$3.45$272.84 million$317.00 million4/29/2026Q1 2026VKTXViking Therapeutics-$1.01-$1.37-$0.36-$1.37N/AN/A3/31/2026Q1 2026INDVIndiviorN/A$0.96N/A$3.45N/A$317.00 million2/27/2026Q4 2025INDVIndivior$0.65$0.82+$0.17$3.95$305.62 million$358.00 million2/26/2026Q4 2025AMPHAmphastar Pharmaceuticals$0.97$0.73-$0.24$0.51$190.48 million$183.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMPHAmphastar PharmaceuticalsN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/AMORMorphoSysN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPHAmphastar Pharmaceuticals0.793.852.82INDVIndiviorN/A0.860.66MORMorphoSys4.981.381.38VKTXViking TherapeuticsN/A5.725.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPHAmphastar Pharmaceuticals65.09%INDVIndivior60.33%MORMorphoSys18.38%VKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipAMPHAmphastar Pharmaceuticals29.60%INDVIndivior0.74%MORMorphoSys0.05%VKTXViking Therapeutics5.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPHAmphastar Pharmaceuticals1,97644.09 million31.04 millionOptionableINDVIndivior1,051121.92 million121.02 millionNot OptionableMORMorphoSys730150.62 million150.55 millionNot OptionableVKTXViking Therapeutics20116.11 million109.95 millionOptionableVKTX, MOR, AMPH, and INDV HeadlinesRecent News About These CompaniesIs Viking Therapeutics a Top Takeover Target?May 23 at 4:31 PM | fool.com2 Stocks That Could Realistically Double by 2030May 22 at 9:46 AM | fool.comViking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Rating of "Moderate Buy" by BrokeragesMay 22 at 2:28 AM | americanbankingnews.comCan Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story?May 21, 2026 | zacks.comViking Therapeutics to Participate at Upcoming Investor ConferencesMay 21, 2026 | finance.yahoo.comViking Therapeutics to Participate at Upcoming Investor ConferencesMay 21, 2026 | prnewswire.comBest Weight Loss Drug Stocks to Buy in 2026May 20, 2026 | fool.comWatch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss PartyMay 18, 2026 | fool.comThree Biotechs That Are Top Takeover TargetsMay 18, 2026 | 247wallst.comThe Bull Case For Viking Therapeutics (VKTX) Could Change Following New Oral VK2735 Obesity Data ReleaseMay 17, 2026 | finance.yahoo.comThis Hot Weight-Loss Drug Stock May Be a Surprise ChallengerMay 15, 2026 | barchart.comCan Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?May 14, 2026 | zacks.comBig Pharma's 5 Hottest Biotech Hunting Grounds: Meet the Category LeadersMay 14, 2026 | 247wallst.comLilly Bets on Next-Generation Obesity Drugs to Stay AheadMay 13, 2026 | zacks.comViking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026May 12, 2026 | prnewswire.comLGND: 1Q:26 Results Highlight Breadth of PortfolioMay 11, 2026 | finance.yahoo.com75,475 Shares in Viking Therapeutics, Inc. $VKTX Bought by Channel Wealth LLCMay 9, 2026 | marketbeat.comVKTX stock slips overnight: Investors pin hopes on fresh weight-loss data as Pfizer joins Eli Lilly, Novo in GLP-1 warMay 6, 2026 | msn.comViking Therapeutics: Market Betting On Big Upside Through 2030May 5, 2026 | seekingalpha.comViking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026May 5, 2026 | finance.yahoo.comViking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026May 5, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesPipelines and Automation: 2 Energy Plays Built for Any Oil PriceBy Chris Markoch | April 26, 2026The DRAM Shake-Up: Samsung Stumbles, Micron Chases $1000By Jeffrey Neal Johnson | May 12, 20262 Stocks to Watch as the Quantum Space Gets More CrowdedBy Nathan Reiff | May 3, 2026Homebuilder Earnings: D.R. Horton Sticks Out as Pulte & NVR Sales TankBy Leo Miller | April 27, 2026Is Everspin Technologies the Next AI Edge Breakout?By Thomas Hughes | May 18, 2026VKTX, MOR, AMPH, and INDV Company DescriptionsAmphastar Pharmaceuticals NASDAQ:AMPH$18.41 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$18.25 -0.16 (-0.87%) As of 05/22/2026 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Indivior NASDAQ:INDV$37.53 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$37.52 -0.02 (-0.04%) As of 05/22/2026 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.MorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 05/22/2026MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Viking Therapeutics NASDAQ:VKTX$30.89 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$30.83 -0.06 (-0.19%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Palantir and Dell Build an AI OS for the Paranoid Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
